(Q39368551)

English

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

multicenter clinical trial

0 references

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Juan P Frías

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cristian Guja

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Elise Hardy

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Azazuddin Ahmed

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Fang Dong

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Peter Öhman

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Serge A Jabbour

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

15 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1004-1016

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

7. Approaches to Glycemic Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dapagliflozin: a review of its use in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of dapagliflozin on renal function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2930267-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(16)30267-4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

release_qaqwfcflnze7tdnscw6myff5qe

1 reference

https://api.fatcat.wiki/v0/release/qaqwfcflnze7tdnscw6myff5qe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39368551&oldid=1843328713"